Everolimus prevents endomyocardial remodeling after heart transplantation

Transplantation

Volumn 92, Issue 10, 2011, Pages 1165-1172

  Hiemann, Nicola E ^a   Wellnhofer, Ernst ^a   Lehmkuhl, Hans B ^a   Knosalla, Christoph ^a   Hetzer, Roland ^a   Meyer, Rudolf ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

Biopsy; Coronary disease; Pathology; Remodeling; Transplantation

Indexed keywords

CYCLOSPORIN A; EOSIN; EVEROLIMUS; HEMATOXYLIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ANGIOCARDIOGRAPHY; ANGIOGENESIS; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART MUSCLE PERFUSION; HEART TRANSPLANTATION; HEART VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGRESSION ANALYSIS;

CORONARY ANGIOGRAPHY; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FIBROSIS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LINEAR MODELS; MALE; MIDDLE AGED; MYOCARDIUM; SIROLIMUS;

EID: 80855139679     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182332886     Document Type: Article

References (29)

1. Anderson KR, Sutton MG, Lie JT. Histopathological types of cardiac fibrosis in myocardial disease. J Pathol 1979; 128: 79.
2. Baandrup U, Olsen EG. Critical analysis of endomyocardial biopsies from patients suspected of having cardiomyopathy. I: Morphological and morphometric aspects. Br Heart J 1981; 45: 475.
3. Porter KE, Turner NA. Cardiac fibroblasts: At the heart of myocardial remodeling. Pharmacol Ther 2009; 123: 255.
4. Onodera H, Matsunaga T, Tamura Y, et al. Enalapril suppresses ventricular remodeling more effectively than losartan in patients with acute myocardial infarction. Am Heart J 2005; 150: 689.
5. Remme WJ. Pharmacological modulation of cardiovascular remodeling: A guide to heart failure therapy. Cardiovasc Drugs Ther 2003; 17: 349.
6. Gramley F, Lorenzen J, Pezzella F, et al. Hypoxia and myocardial remodeling in human cardiac allografts: A time-course study. J Heart Lung Transplant 2009; 28: 1119.
7. Armstrong AT, Binkley PF, Baker PB, et al. Quantitative investigation of cardiomyocyte hypertrophy and myocardial fibrosis over 6 years after cardiac transplantation. J Am Coll Cardiol 1998; 32: 704.
8. Koch A, Geil-Bierschenk C, Rieker R, et al. Morphometric changes of the right ventricle in the first two weeks after clinical heart transplantation: Analysis of myocardial biopsies from patients with complicated versus uncomplicated course. Eur J Cardiothorac Surg 2006; 30: 370.
9. Simler NR, Howell DC, Marshall RP, et al. The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats. Eur Respir J 2002; 19: 1124.
10. Azzola A, Havryk A, Chhajed P, et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004; 77: 275.
11. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847.
12. Hiemann NE, Wellnhofer E, Knosalla C, et al. Prognostic impact of microvasculopathy on survival after heart transplantation-Evidence from 9713 endomyocardial biopsies. Circulation 2007; 116: 1274.
13. Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 2002; 11: 1845.
14. Ballard VL. Stem cells for heart failure in the aging heart. Heart Fail Rev 2010; 15: 447.
15. Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460: 392.
16. Yamani MH, Haji SA, Starling RC, et al. Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome. J Am Coll Cardiol 2002; 39: 970.
17. Mehra MR, Crespo-Leiro MG, Dipchand A, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant 2010; 29: 717.
18. Schmauss D, Weis M. Cardiac allograft vasculopathy: Recent developments. Circulation 2008; 117: 2131.
19. Wellnhofer E, Stypmann J, Bara CL, et al. Angiographic assessment of cardiac allograft vasculopathy: Results of a Consensus Conference of the Task Force for Thoracic Organ Transplantation of the German Cardiac Society. Transpl Int 2010; 23: 1094.
20. Kapadia SR, Nissen SE, Ziada KM, et al. Development of transplantation vasculopathy and progression of donor-transmitted atherosclerosis: Comparison by serial intravascular ultrasound imaging. Circulation 1998; 98: 2672.
21. Satonaka H, Suzuki E, Nishimatsu H, et al. Calcineurin promotes the expression of monocyte chemoattractant protein-1 in vascular myocytes and mediates vascular inflammation. Circ Res 2004; 94: 693.
22. Sudhir K, MacGregor JS, DeMarco T, et al. Cyclosporine impairs release of endothelium-derived relaxing factors in epicardial and resistance coronary arteries. Circulation 1994; 90: 3018.
23. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621.
24. Schaffer SA, Ross HJ. Everolimus: Efficacy and safety in cardiac transplantation. Expert Opin Drug Saf 2010; 9: 843.
25. Gao SZ, Alderman EL, Schroeder JS, et al. Accelerated coronary vascular disease in the heart transplant patient: Coronary arteriographic findings. J Am Coll Cardiol 1988; 12: 334.
26. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462.
27. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710.
28. Hiemann NE, Wellnhofer E, Hetzer R, et al. Small vessel disease after heart transplantation: Impact of immunological and nonimmunologic risk factors. Transpl Int 2005; 18: 908.
29. Rowan RA, Billingham ME. Sustained myocardial hypertrophy seven years or more after heart transplantation: A morphometric study of endomyocardial specimens. J Heart Lung Transplant 1992; 11 (2 Pt 1): 350.